{'fraction_non_alphanumeric': 0.033619456366237484, 'fraction_numerical': 0.024320457796852647, 'mean_word_length': 4.733606557377049, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
THIAMINE RESPONSIVE ANAEMIA

However, only 85% of these cells were positive for CD5 indicating the presence of CD5( ) MER( + ) B1( +) cells in the CLL patients peripheral blood. It has been shown that stimulation of normal B cells leads to various changes in morphology and immunological phenotype (Corradi et al. 1987; Visser & Poppema, 1990). It has also been reported that phorbol ester treatment of normal B cells induces phenotypes similar to those found in B-CLL patients (Calligaris-Cappio et al, 1985: Visser & Poppema, 1990). This finding is also confirmed by our present work and mitogen treatment caused significant elevation of mouse erythrocyte receptor, a known marker of immature B cells and CLL lymphocytes, on the cells. Mitogen stimulation also caused increased CD5 expression of the B cells. CD5 positive B cells are the major B-cell population in the fetal period forming primary follicles in lymph nodes and spleen (Antin et al. 1986). Visser & Poppema (1990) have suggested that increased CD5 on the peripheral B-cells is possibly an activation marker for B cells. Indeed, in our study the number of CD5 positive cells paralleled increases in MER and other activation markers such as HLA-DR and IL-2R. These results indicate that increased mouse erythrocyte rosette receptor in the normal peripheral B cell population can also be regarded as an activation marker. However, the